...
首页> 外文期刊>statistics in medicine >Data monitoring boards in the pharmaceutical industry
【24h】

Data monitoring boards in the pharmaceutical industry

机译:制药行业的数据监控板

获取原文
           

摘要

AbstractThis paper describes the characteristics and responsibilities of data monitoring boards (DMBs) employed in clinical trials sponsored by pharmaceutical firms. These DMBs are compared with DMBs in clinical trials sponsored by the National Institutes of Health (NIH). All trials discussed are assumed to be phase III pre‐market clinical trials. It is seen that DMBs in pharmaceutical industry trials have more limited responsibilities than DMBs in NIH clinical trials. Pharmaceutical industry DMBs are employed to add credibility to trials by certifying critical clinical trial processes such as patient evaluability, interim analyses, evaluation of efficacy endpoints, and safety monitoring. An example of a pharmaceutical industry DMB's charter and operations is presented for a clinical trial for the prevention of stress ulcers. The specific problems encountered when a pharmaceutical industry clinical trial is conducted by NIH under the auspices of an NIH‐appointed DMB are discussed. New uses for DMBs in the pharmaceutical industry are introduced and future trends in the industry with respect to DMBs are exami
机译:摘要本文介绍了制药公司赞助的临床试验中采用的数据监测委员会(DMB)的特点和职责。这些 DMB 与美国国立卫生研究院 (NIH) 赞助的临床试验中的 DMB 进行比较。所讨论的所有试验均假定为III期上市前临床试验。可以看出,制药行业试验中的 DMB 比 NIH 临床试验中的 DMB 具有更有限的责任。制药行业 DMB 通过认证关键的临床试验流程(如患者可评估性、中期分析、疗效终点评估和安全性监测)来增加试验的可信度。以制药行业为例,介绍了DMB的章程和运营,用于预防应激性溃疡的临床试验。讨论了 NIH 在 NIH 指定的 DMB 主持下进行制药行业临床试验时遇到的具体问题。介绍了DMB在制药行业中的新用途,并研究了DMB行业的未来趋势。

著录项

  • 来源
    《statistics in medicine》 |1993年第5‐6期|555-561|共页
  • 作者

    Jay Herson;

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 英语
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号